FWA
CBIO

Freedom Wealth Alliance’s Crescent Biopharma CBIO Stock Holding History

Freedom Wealth Alliance’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-95
Closed -$28.6K – 222
2022
Q4 		$28.6K Buy
+95
New +$14K 0.04% 160

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Freedom Wealth Alliance's CBIO Position: Q1 2023 in Review

Freedom Wealth Alliance sold out of Crescent Biopharma (CBIO) in Q1 2023, closing a stake of 95 shares — an estimated $28.6K sold.

Freedom Wealth Alliance first reported a position in CBIO in Q4 2022 and held it in 1 quarter. The position peaked at $28.6K in Q4 2022. 54 funds tracked by Wall St. Rank hold CBIO as of Q1 2023.

  • Freedom Wealth Alliance reported no remaining Crescent Biopharma position as of Q1 2023 after selling out during the quarter.
  • Freedom Wealth Alliance sold 95 Crescent Biopharma shares in Q1 2023, an estimated $28.6K.
  • Freedom Wealth Alliance first reported a position in Crescent Biopharma in Q4 2022 and held it in 1 quarter.
  • Freedom Wealth Alliance's Crescent Biopharma position peaked at $28.6K in Q4 2022.
  • 54 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2023.

Based on Freedom Wealth Alliance's 13F filing for Q1 2023, filed 25 Apr 2023.